Poor Sleep, Daytime Sleepiness May Lead To Dementia: Read Details Here

Updated Dec 19, 2024 | 08:00 PM IST

SummaryLatest research has established a potential link between poor sleep and the development of dementia, particularly a condition called motoric cognitive risk syndrome (MCR).
Daytime Sleepiness

Daytime Sleepiness (Credit: Canva)

Experiencing daytime sleepiness is something that is usually perceived as a minor inconvenience, but for older adults, it could be an early warning sign of Dementia. This neurodegenerative disease leads to the progressive decline of brain cells. This eventually

affects memory, cognition, and personality, making everyday tasks more difficult. As one of the fastest-growing neurological disorders across the world, dementia poses a significant health threat to ageing populations.

Is Dementia Linked To Poor Sleep?

Daytime sleepiness is a direct result of poor sleep quality. Now, a recent research, published in the journal Neurology, highlighted a potential link between poor sleep and the development of dementia, particularly a condition called motoric cognitive risk syndrome (MCR). The study found that 35.5% of participants who reported extreme daytime sleepiness developed MCR, which is a precursor to dementia.

For this study, researchers followed 445 older adults (average age 76) over three years, aiming to determine whether poor sleep could increase the risk of mild cognitive impairment (MCI), which often leads to dementia. At the start, none of the participants had MCI, but by the end of the study, 36 individuals had developed the condition.

The researchers discovered that participants with poor sleep were more likely to develop MCI compared to those who slept well. However, when depression symptoms were taken into account, the link between poor sleep and MCI became less pronounced, suggesting that while sleep issues are a concern, mental health also plays a key role in dementia risk.

To assess sleep quality, the Pittsburgh Sleep Quality Index (PSQI) was used, evaluating factors such as sleep duration, disturbances, and daytime alertness. Among these, "daytime dysfunction"—defined as excessive sleepiness and low energy during the day—was most strongly associated with an increased risk of MCI. Those experiencing daytime dysfunction were more than three times as likely to develop MCI as those who didn’t report such symptoms.

There are many types of dementia:

Dementia is not a specific disease. According to the Centers for Disease Control and Prevention (CDC), it is an overall term that describes a decline in mental ability that interferes with daily life. People with dementia often have symptoms like trouble remembering, thinking, or making everyday decisions. These symptoms tend to get worse over time.

Alzheimer’s disease is the most common type of dementia, and it mostly affects the elderly. Each form of dementia has a different cause. Though dementia mostly affects older adults, it is not a part of normal ageing. An estimated 6.7 million older adults have Alzheimer's disease in the United States. That number is expected to double by 2060, as per data from the CDC.

In 2022, 3.8% of men and 4.2% women in US were diagnosed with dementia. The percentage of people increase with age from 1.7% for those aged 65-74 to 13.1% for those aged 85 and older. Alzheimer's accounts for 60 to 80% of all dementia cases and it is most prevalent in California, Florida, and Texas, as these states have the highest number of people.

End of Article

Malaria Cases, Deaths Fall Nearly 80% In India, But Climate Change Could Pose New Threat: President Murmu

Updated Nov 17, 2026 | 09:32 PM IST

SummaryThe President warned that climate change, unplanned urbanization and insecticide resistance could hinder malaria elimination. She also flagged rising temperatures and shifting monsoon patterns as growing challenges for dengue.
Malaria Cases, Deaths Fall Nearly 80% In India, But Climate Change Could Pose New Threat: President Murmu

Credit: Health Ministry/X

Malaria cases and deaths in India declined by nearly 80% between 2015 and 2025, President Droupadi Murmu said on Tuesday, while warning that climate change, unplanned urbanization and growing mosquito resistance could create new challenges for malaria elimination.

Speaking at the inauguration of the Golden Jubilee celebrations of the Indian Council of Medical Research–National Institute of Malaria Research (ICMR–NIMR), the President called for sustained vigilance, stronger surveillance and greater community participation to achieve malaria elimination.

India Makes Progress In Malaria Control

The President noted that malaria remains a serious public health challenge in several countries, including India.

Recalling the situation at the time of independence, she said the vector-borne disease was among the country's most critical public health challenges. She also shared her personal observations of how malaria affected people's lives.

"During the monsoon season, fever was often accepted as an inevitable hardship of life. Children were unable to attend school, while farmers and laborers were often left unable to work for days on end. For the people, malaria was not merely a health issue—it was deeply intertwined with their livelihoods, education, and future," she said.

India has since made significant progress through sustained public health interventions. Between 2015 and 2025, malaria cases and deaths declined by nearly 80%, while the number of high-burden districts fell from 155 to 33.

As many as 160 districts reported zero indigenous malaria cases between 2022 and 2025, reflecting progress in interrupting local transmission and implementing targeted malaria control and elimination measures.

Calling the progress "remarkable", the President credited improved healthcare services, modern diagnostic techniques, effective medicines, mosquito-control campaigns and community participation for curbing the disease.

Also read: El Niño Could Worsen Dengue, Malaria And Heat Illness: Why WHO Declared A Health Emergency

Stronger Surveillance Needed To Eliminate Malaria

Despite the progress, malaria remains a challenge in certain regions, the President said, stressing the need for "sustained vigilance and effective efforts" to eliminate the disease.

She highlighted the importance of robust systems for malaria testing, treatment, surveillance and mosquito control.

Research aimed at developing new drugs and vaccines, along with public awareness and community participation, will also be vital for malaria elimination, she said.

Climate Change Could Pose New Challenges

The President warned that climate change, unplanned urbanization and growing mosquito resistance to insecticides could create new obstacles to malaria elimination efforts.

She also urged citizens to contribute to prevention efforts by avoiding water stagnation, eliminating mosquito breeding sites and maintaining a clean environment.

Beyond malaria, she noted that rising global temperatures and shifting monsoon patterns are further intensifying the challenge posed by dengue.

India Aims To Eliminate Malaria By 2030: Health Minister

Read More: Will India Be Malaria-Free By 2030? 160 Districts Report Zero Cases Over 3 Years; Burden Falls 80% In A Decade

Addressing the gathering, Union Minister of Health and Family Welfare Jagat Prakash Nadda said India's progress in malaria control over the past decade was the result of a comprehensive approach involving research on mosquito behaviour and malaria parasites, community participation, effective prevention, early diagnosis and appropriate treatment.

Highlighting India's progress in malaria control, Nadda noted that the country, which accounts for approximately 16% of the global population, contributes around 0.7% of global malaria cases and 0.6% of malaria deaths.

The Union Minister also appreciated India's exit from the WHO's High Burden to High Impact initiative and expressed confidence in achieving malaria elimination by 2030.

"We will eliminate malaria by 2030 by bringing about the necessary changes in our strategies and policies," he said, calling upon ICMR–NIMR to work with renewed commitment.

The Minister also highlighted ICMR's contributions to medical innovation, including MedTech Mitra, Patent Mitra and ELISA-based molecular diagnostics for dengue, chikungunya, Japanese encephalitis and other infectious diseases.

End of Article

Trials For Deadly Childhood Brain Cancer Stalled After Trump Administration Shuts Down 27-Year Research Consortium

Updated Nov 17, 2026 | 06:00 PM IST

SummaryPediatric Brain Tumor Consortium (PBTC)'s shutdown has impacted multiple clinical trials and research of aggressive childhood brain cancer like diffuse intrinsic pontine glioma (DIPG) and ependymoma.
Trials For Deadly Childhood Brain Cancer Stalled After Trump Administration Shuts Down 27-Year Research Consortium

Credit: AI-generated image

Clinical trials investigating experimental treatments for rare, aggressive childhood brain cancers have been disrupted after the closure of a US research consortium that was in operation for 27 years.

The shutdown of the Pediatric Brain Tumor Consortium (PBTC), after the National Cancer Institute (NCI) declined to renew its funding, has caused significant delays and rendered desperate families searching for alternative treatment options.

The consortium was composed of 16 leading children's hospitals and academic medical centres across the US, aiming to investigate new treatments for aggressive brain tumours, including diffuse intrinsic pontine glioma (DIPG) and ependymoma.

The NCI informed consortium leaders about the decision in August 2025, ending its approximately $4 million annual grant. Eight ongoing clinical trials were subsequently halted, according to The New York Times.

The consortium formally dissolved in September 2026. Researchers say the disruption has affected not only ongoing studies but also the infrastructure and resources needed to develop new treatments for childhood brain cancers.

DIPG Is One Of The Most Aggressive Childhood Brain Cancers

Also read: Losing Balance While Walking? Doctors Explain When It Could Be A Neurological Warning Sign

DIPG is a rare, aggressive brain tumour that usually affects children between four and 10 years of age. It develops in the pons, a part of the brainstem which is responsible for essential functions like breathing, heart rate, coordination and balance.

Since the tumour grows within critical brain tissue and spreads through the brainstem, it cannot be removed through surgery. Clinicians describe it “like sand in grass”.

Radiation therapy is commonly used to fight the tumour but its benefits are temporary. There is currently no established treatment. The average survival after diagnosis is approximately nine to 12 months.

With limited treatment options, clinical trials investigating experimental therapies are a need of the hour for children suffering from DIPG.

Research And Clinical Trials That Were Affected Due To Funding Closure

Also read: AIIMS Delhi Performs India's First Open Fetal Surgery To Repair Spina Bifida

The closure disrupted several studies exploring experimental treatments for childhood brain tumours.

One of the affected studies, PBTC-059, was a Phase 1 trial investigating CAR-T cell therapy in children with ependymoma. CAR-T therapy entails modifying a patient's immune cells to identify and attack cancer cells.

Another study, PBTC-N14, was discontinued too. Researchers at Memorial Sloan Kettering Cancer Center were investigating whether cerebrospinal fluid samples could provide genetic information similar to that obtained through an invasive brain biopsy, reducing the need for surgery in some children.

Researchers were also exploring other experimental options for DIPG, including cancer vaccines and devices that can deliver electrical stimulation to the brain.

According to the NCI's updated information, some paused trials are expected to reopen to patient enrolment in late 2026 or early 2027. But the interruption has created a significant gap and delay for families who were previously able to access these trials.

27 Years Of Research Data At Stake

Also read: Beth Dobbin's Myalgic Encephalomyelitis Campaign Gains Support From 360 Sportspeople: Why Are They Urging UK PM To Act?

The consequences of the consortium's closure extend well beyond clinical trial enrolment and patient welfare. At St. Jude Children's Research Hospital, 27 years of research data involving more than 2,000 children with rare brain tumours had to be archived.

Hundreds of biological samples, including tumour tissue, blood and spinal fluid collected from patients, also had to be returned to hospitals or destroyed if they could not be retained.

Researchers have raised concerns that losing the consortium's dedicated infrastructure and centralised data-access system could make it harder for scientists to resume these studies and build on previous findings.

Ira Dunkel, a paediatric oncologist at Memorial Sloan Kettering Cancer Center and former chair of the consortium, described the closure as “catastrophic” and one of the worst professional moments of his career.

Why Did The US Government Shut Down PBTC?

The NCI said the decision was taken to improve efficiency by moving the consortium's data into the larger Pediatric Early Phase Clinical Trials Network. The institute also said enrolment in some consortium studies had slowed.

But researchers argued that the smaller patient populations and the highly targeted nature of experimental treatments make specialised research areas particularly important.

After the decision, NCI announced that approximately $4 million would be allocated to the larger network to strengthen paediatric brain tumour research and accelerate Phase 1 clinical trials.

The $4 million grant also seemed insufficient compared to the $732 million that the NIH spends annually on childhood cancer. But according to Dunkel, it was “hugely important”.

But researchers and patient support groups have questioned whether the larger network can immediately and effectively replace the consortium's specialised expertise, proven collaborations and research infrastructure.

A bipartisan group of lawmakers from New York called wrote to Health and Human Services Secretary Robert F. Kennedy Jr., urging to reverse the decision. “We cannot afford to take this step backward,” the group said.

Families dealing with aggressive childhood brain cancers are helpless in the light of consortium closure. With some children having less than a year after diagnosis, such setbacks mean losing access to potentially life-saving or extending experimental treatment opportunities that may not become available again in time.

End of Article

India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Updated Nov 17, 2026 | 04:15 PM IST

SummaryThe National Health Accounts (NHA) Estimates for India 2023–24 revealed that government health expenditure more than tripled over the past decade, rising from ₹1,29,778 crore in 2013–14 to ₹4,14,196 crore in 2023–24.
India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Credit: AI Image

India’s social security expenditure on health nearly doubled as a share of Total Health Expenditure, rising from 6% in 2013–14 to 11% in 2023–24, according to the Union Health Ministry. The spending, estimated to have crossed Rs 1 lakh crore, aims to protect individuals and families against the financial risks associated with medical treatment.

This growth has been led by whopping contributions of the government's flagship health insurance schemes such as Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB PM-JAY), state-specific health insurance schemes, social health insurance and medical expenditure for government employees.

Private health insurance expenditure also increased, rising from 3.4% of Total Health Expenditure in 2013-14 to 10.2% in 2023-24.

Government Health Expenditure Triples In A Decade

Also read: Ayushman Bharat Turns 8: PM Modi Highlights Record Savings On Medical Expenses

According to the National Health Accounts (NHA) Estimates for India 2023-24, released by the Ministry of Health and Family Welfare, India’s government health expenditure nearly tripled over the past decade, increasing from Rs 1,29,778 crore in 2013-14 to Rs 4,14,196 crore in 2023-24.

The government’s share of Total Health Expenditure (THE) increased by 14.9 percentage points over the decade, representing a rise of nearly 52%.

The report also highlighted an increase in per-capita government health expenditure and a decline in households’ out-of-pocket spending on healthcare.

“A healthier India. Lower financial burden. Stronger healthcare for all!” Union Health Minister JP Nadda said in a post on X while sharing the data.

"The National Health Accounts 2023–24 tell a powerful story of India’s healthcare transformation over the last decade," he added.

India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Per-Capita Government Health Spending Rises 184% In A Decade

Per-capita government health expenditure increased by 184% over the decade, nearly tripling from Rs 1,042 in 2013-14 to Rs 2,959 in 2023-24.

Spending crossed Rs 2,000 in 2019-20, reaching Rs 2,014, and rose further to Rs 2,328 in 2020-21.

The highest per-capita expenditure was recorded in 2021-22 at Rs 3,169, driven by emergency COVID-19 spending. It subsequently declined by 12.1% to Rs 2,786 in 2022-23 before increasing by 6.2% to Rs 2,959 in 2023-24.

The year-on-year growth rate peaked at 36.1% in 2021-22. Among the years that recorded an increase, the lowest growth was 6.2% in 2023-24.

“These are not just numbers. They reflect a decade of sustained efforts to make quality healthcare more affordable,” Nadda said.

He attributed the progress to initiatives such as Ayushman Bharat and Ayushman Arogya Mandirs under Prime Minister Narendra Modi. He also highlighted expanded access to free medicines and diagnostics as part of efforts to strengthen healthcare delivery.

"Our commitment is simple: No family should have to choose between its health and its financial well-being. A Swasth Bharat is the foundation of a Viksit Bharat!" Nadda said.

Public Investment In Primary Healthcare Triples

Public investment in primary healthcare also nearly tripled over the decade, rising from Rs 50,010 crore in 2013-14 to Rs 1,52,771 crore in 2023-24, according to the NHA estimates.

Out-Of-Pocket Health Expenditure Falls

Read More: India Digitalizes Health Records Of 100 Crore People Under Ayushman Bharat

The share of out-of-pocket expenditure (OOPE) in Total Health Expenditure declined from 64.2% in 2013-14 to 42.7% in 2023-24, a drop of 21.5 percentage points.

This indicates that households are paying a smaller share of overall healthcare costs directly, while other financing sources, including government spending and health insurance, account for a larger share.

Government Initiatives Expanding Access To Affordable Healthcare

The Ministry also highlighted several initiatives aimed at improving access to affordable healthcare across the country. These include:

  • Free Drugs and Diagnostics Initiatives
  • Pradhan Mantri National Dialysis Programme
  • Pradhan Mantri Bhartiya Janaushadhi Pariyojana
  • Affordable Medicines and Reliable Implants for Treatment (AMRIT) pharmacies.

End of Article